Viewing StudyNCT06463587

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-07-17 @ 10:55 AM
Last Modification Date: 2024-10-26 @ 3:32 PM
Study NCT ID: NCT06463587
Status: RECRUITING
Last Update Posted: 2024-07-01
First Post: 2024-06-11
Brief Title: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis MyClad
Sponsor: Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
Organization: Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Organization Data

Organization: Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
Class: INDUSTRY
Study ID: MS700568_0183
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor: Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
Lead Sponsor Class: INDUSTRY
Responsible Party: None
Responsible Party Title: None
Responsible Party Type: SPONSOR
Responsible Party Affiliation: None
Old Name: None
Old Organization: None

Collaborators

Name Class
EMD Serono Research Development Institute Inc INDUSTRY